In this biography
Quick facts
- Born
- October 1957
- Birthplace
- Not independently established
- Country
- South Korea
- Nationality
- Not independently established
- Known for
- Celltrion and the development of a biosimilar business
- Birth precision
- October 1957
- Celltrion founding
- 2002
- US regulatory milestone
- Inflectra approval, 5 April 2016
- EY recognition
- 2021
Why this life matters
His career connects entrepreneurial organisation with manufacturing, scientific teams and regulatory review, without assigning a medicine’s entire development to its founder.
Timeline
Key moments
Industrial work
Industrial-engineering study and Daewoo employment preceded the biotech venture.
Celltrion
Founder statement dates the company’s establishment.
US approval
FDA approved Inflectra as a biosimilar, not as interchangeable in that decision.
Entrepreneur award
EY named Seo its World Entrepreneur of the Year.
An industrial career preceded biotechnology
The UK company register gives Jungjin Seo’s birth month and year as October 1957. EY’s 2021 career account describes industrial-engineering study at Konkuk University and work at Daewoo Motor. The account also recalls taxi-driving work during his education and the loss of employment amid the automaker’s financial troubles after the Asian financial crisis. These are details in an award organisation’s retrospective profile, not a complete employment file. They place the later biotechnology venture within an earlier industrial career without attributing the conduct of other Daewoo executives to Seo.
The new venture required an organisation beyond one founder
Celltrion’s founder statement dates its establishment to 2002. EY describes Seo and colleagues exploring several business possibilities before concentrating on biopharmaceuticals. The venture therefore involved identifying an opportunity, assembling people and building a manufacturing organisation. The founder’s role is important without becoming a claim that he personally discovered the reference medicines or performed every laboratory experiment. Capital figures in the award release and company statement differ; this profile does not choose between them or turn an uncertain founding sum into a measure of the enterprise’s later success.
A biosimilar business depended on scientific and regulatory work
The company’s account emphasises biosimilars and describes the ambition to expand access to biological medicines. That is a stated business purpose rather than an independently measured result. The 2016 FDA announcement supplies a more specific milestone: approval of Inflectra, infliximab-dyyb, as biosimilar to Remicade. It describes multiple categories of evidence supporting the decision. A founder’s commercial vision and the evidence evaluated by a regulator are related parts of the story, but they answer different questions about how the company and its products developed.
The approval record named several institutional roles
FDA’s 5 April 2016 announcement identifies Celltrion as manufacturer for Hospira and identifies Janssen’s Remicade as the reference product. It also explicitly describes that approval as biosimilar rather than interchangeable. These details should remain attached to the date and jurisdiction of the decision. They are not a current treatment recommendation or a claim that every proposed use in an earlier review was licensed. The record also prevents a solitary-founder account: reference-product development, manufacturing, distribution and regulatory assessment were distinct activities involving different organisations and professional teams.
Sources for this section: [4]
Recognition is evidence of an award, not every outcome
On 10 June 2021 EY named Seo World Entrepreneur of the Year. Its release identified him as honorary chairman at that time and praised the development of Celltrion. The award establishes recognition by that organisation; its promotional account is not an independent evaluation of every patient outcome or affordability claim. The founder statement also credits colleagues and stresses meeting partners and healthcare professionals in person. These accounts are useful for understanding how Seo presents leadership and how others celebrated it, while still requiring separate evidence for clinical, commercial or social effects.
Institutional records keep the biography grounded
The registrar entry, the founder statement, the award release and the FDA announcement serve different purposes. Together they support a career spanning industrial work, entrepreneurial organisation and a regulatory milestone. The register is used only for the reported birth month and year, not for a personal-wealth calculation. An older honorary-chairman label is not repeated as a current office without checking a later record. Seo’s significance lies in helping build the institution through which scientific, manufacturing and commercial work could proceed, rather than replacing those contributions with a single heroic invention story.
Quick answers
Frequently asked questions about Seo Jung-jin
- Does a founder title establish authorship of a medicine?
- No. The records distinguish entrepreneurial organisation, scientific work, manufacturing and regulatory assessment.
- Is the 2016 approval described as interchangeable?
- No. FDA expressly distinguished biosimilar approval from interchangeability in that dated announcement.
Keep exploring
Lives connected to this story
- Kim Woo-choong
Place the earlier Daewoo employment in a separate corporate history.
- Hwang Chul-joo
Compare another entrepreneur connecting industrial technology with an operating company.
- Suh Kyung-bae
Explore a different research-and-manufacturing business career.
Sources and further reading
Explore the evidence
These references support the biography and offer further reading. Official records, first-person accounts and independent reporting provide different perspectives; image records document attribution and licensing.
- 1. UK Companies HouseCelltrion Healthcare UK: Jungjin Seo control record
Only named registrar entry read in original HTML for October 1957 birth month/year. Current control percentages, address and identity-verification deadlines are not republished or converted to personal wealth.
- 2. EY, issuer release distributed by PRNewswireJungJin Seo named EY World Entrepreneur of the Year 2021
Actual award/body and selected founder-career paragraphs read: 10 June 2021 award, industrial-engineering study, Daewoo employment/business disruption and later biotech venture. Award publicity is not an independent clinical/affordability audit. Capital amount differs from founder-site account and is omitted.
- 3. Celltrion USA / Jungjin SeoOur Story: founder’s statement
Actual founder statement read for 2002 founding, partnership/onsite-leadership emphasis and 2021 award acknowledgment. Undated current-office copy, patient totals, capacity, market superlatives and unverified priority claims not adopted.
- 4. US Food and Drug AdministrationFDA approves Inflectra, a biosimilar to Remicade, 5 April 2016
Actual complete 2016 news-release body read, including licensed-use list, biosimilarity definition, not-interchangeable statement, manufacturer/distributor roles and evidence categories. No current substitution/treatment recommendation or assumption that 2016 status remains unchanged. Broken linked approval-letter endpoint 404 is retained, not claimed read.